Moderna, Inc. (NASDAQ:MRNA) Shares Sold by National Bank of Canada FI

National Bank of Canada FI lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 56.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 310,380 shares of the company’s stock after selling 398,681 shares during the quarter. National Bank of Canada FI owned 0.08% of Moderna worth $30,867,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of MRNA. The Manufacturers Life Insurance Company raised its position in shares of Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after buying an additional 1,690,341 shares during the period. Invesco Ltd. raised its position in Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares during the period. Wellington Management Group LLP lifted its stake in shares of Moderna by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after purchasing an additional 476,201 shares during the last quarter. Bamco Inc. NY grew its holdings in shares of Moderna by 4,863.6% during the 3rd quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after purchasing an additional 418,269 shares during the period. Finally, abrdn plc increased its position in shares of Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the sale, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the sale, the director now directly owns 2,026,931 shares in the company, valued at $224,827,186.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. Insiders have sold a total of 139,954 shares of company stock valued at $14,822,576 in the last 90 days. 15.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on MRNA. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Oppenheimer boosted their price objective on Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a research report on Friday. Canaccord Genuity Group raised their target price on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday. Finally, HSBC reissued a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $129.55.

Moderna Stock Down 2.3 %

MRNA stock opened at $122.13 on Tuesday. The firm’s 50-day moving average is $105.61 and its two-hundred day moving average is $94.76. The company has a market capitalization of $46.81 billion, a price-to-earnings ratio of -7.79 and a beta of 1.57. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same period in the prior year, the company earned $0.19 EPS. Moderna’s revenue was down 91.0% on a year-over-year basis. On average, analysts forecast that Moderna, Inc. will post -7.47 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.